Release Details

Block Listing Application

May 16, 2016

16 May 2016


Block Listing Application

LivaNova PLC (the “Company”) announces that it has made an application to the UK Listing Authority and the London Stock Exchange for the block listing of 1,012,137 ordinary shares of £1.00 each (the “Ordinary Shares”) to be admitted to the standard segment of the Official List and to trading on the Main Market of the London Stock Exchange. The Ordinary Shares have been, or, will be, allotted and issued pursuant to vesting of certain equity awards of the Company in connection with the Company’s incentive award schemes.

The Ordinary Shares shall rank pari passu with the existing issued Ordinary Shares of the Company. Admission of the Ordinary Shares is expected to be effective, and dealings in the Ordinary Shares are expected to commence at 8:00 am on 17 May 2016.

About LivaNova

LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm Management, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and is admitted to the standard listing segment of the Official List of the UK’s Financial Conduct Authority and to trading on the London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit, or contact:

Investor Relations and Media:
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332